BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports. Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, January 21st. Get BioXcel Therapeutics alerts:Check Out Our Latest Stock Analysis on BioXcel TherapeuticsBioXcel Therapeutics Price PerformanceShares of BTAI opened at $1.62 on Wednesday. BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. BioXcel Therapeutics Company Profile(Get Free Report)BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology.